AIM ImmunoTech Inc. (AIM): Nasdaq/NYSE listing notice — AIM ImmunoTech gets second NYSE American noncompliance notice for negative $3.9M equity

AIM ImmunoTech Inc.

NYSE American warned AIM on June 17, 2025 for failing minimum stockholders' equity: negative $3.9M as of March 31, 2025.
Company has losses in five most recent fiscal years; similar warning was issued on Dec 17, 2024.
Compliance plan accepted Feb 26, 2025; AIM has until June 11, 2026 to regain compliance.
AIM common stock recommenced trading June 17 under symbol 'AIM'; notice does not affect trading.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

AIM ImmunoTech Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 1003(a)(ii), 1003(a)(iii)

Exact text from the filing

June 17, 2025, AIM ImmunoTech Inc. (the “Company”) received a warning notification (the “Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing o

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-015861

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.